Lone Baandrup

Lone Baandrup

Auto-generated profile, based on publicly available information

Lone Baandrup

Mental Health Center Copenhagen, Copenhagen University Hospital - Mental Health Services CPH, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LBLone Baandrup
Lone Baandrup
BEBjørn H Ebdrup
Bjørn H Ebdrup
JRJesper Ø Rasmussen
Jesper Ø Rasmussen
JLJane Lindschou
Jane Lindschou
CGChristian Nyfeldt Gluud
Christian Nyfeldt Gluud
BGBirte Y Glenthøj
Birte Y Glenthøj

6 January 2020 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
LBLone Baandrup
Lone Baandrup
Schizophrenia is a severe mental disorder characterized by a heterogeneous symptom profile which comprises a clinical platform for widespread use of polypharmacy even though antipsychotic monotherapy is the recommended treatment regimen. This narrative review provides a summary of the current gap between evidence and practice for use of antipsychotic combination therapy in patients with schizophrenia. Antipsychotic polypharmacy is frequently prescribed instead of following international consensus of clozapine monotherapy in treatment‐resistant patients. Antipsychotic‐benzodiazepine combination therapy clearly has a role in the treatment of acute agitation whereas there is no evidence to support an effect on core schizophrenia symptoms when chronically prescribed. Antidepressants are typically added to antipsychotic treatment in case of persistent negative symptoms. Available evidence suggests that antidepressants may improve negative symptom control in schizophrenia. Combining an antipsychotic with an antiepileptic is not supported by any firm evidence, but individual mood stabilizers have come out positively in single trials. Generally, the evidence base for polypharmacy in schizophrenia maintenance treatment is sparse but may be warranted in certain clinical situations. Therapeutic benefits and side effects should be carefully monitored and considered to ensure a beneficial risk‐benefit ratio if prescribing polypharmacy for specific clinical indications.

6 July 2023 in eClinicalMedicine
Verified
Journal Article
Open access
Mina HändelMina Händel
Mina Händel
HAHenning Keinke Andersen
Henning Keinke Andersen
AUAnja Ussing
Anja Ussing
AVAnne Virring
Anne Virring
PJPoul Jennum
Poul Jennum
HCHenriette Edemann Callesen
Henriette Edemann Callesen
Currently, melatonin is used to treat children and adolescents with insomnia without knowing the full extent of the short-term and long-term consequences. Our aim was to provide clinicians and guideline panels with a systematic assessment of serious—and non-serious adverse events seen in continuation of melatonin treatment and the impact on pubertal development and bone health following long-term administration in children and adolescents with chronic insomnia. We searched PubMed, Embase, Cinahl and PsycINFO via Ovid, up to March 17, 2023, for studies on melatonin treatment among children and adolescents (aged 5–20 years) with chronic insomnia. The language was restricted to English, Danish, Norwegian, and Swedish. Outcomes were non-serious adverse events and serious adverse events assessed 2–4 weeks after initiating treatment and pubertal development and bone health, with no restriction on definition or time of measurement. Observational studies were included for the assessment of long-term outcomes, and serious and non-serious adverse events were assessed via randomised studies. The certainty of the evidence was assessed using Grades of Recommendation, Assessment, Development and Evaluation (GRADE). The protocol is registered with the Danish Health Authority. We identified 22 randomised studies with 1350 patients reporting on serious—and non-serious adverse events and four observational studies with a total of 105 patients reporting on pubertal development. Melatonin was not associated with serious adverse events, yet the number of patients experiencing non-serious adverse events was increased (Relative risk 1.56, 95% CI 1.01–2.43, 17 studies, I2 = 47%). Three studies reported little or no influence on pubertal development following 2–4 years of treatment, whereas one study registered a potential delay following longer treatment durations (>7 years). These findings need further evaluation due to several methodological limitations. Children who use melatonin are likely to experience non-serious adverse events, yet the actual extent to which melatonin leads to non-serious adverse events and the long-term consequences remain uncertain. This major gap of knowledge on safety calls for caution against complacent use of melatonin in children and adolescents with chronic insomnia and for more research to inform clinicians and guideline panels on this key issue. The Danish Health Authority. The 10.13039/100014547 Parker Institute , Bispebjerg and Frederiksberg Hospital, supported by the 10.13039/100001275 Oak Foundation .

1 November 2015 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
PJPoul Jennum
Poul Jennum
LBLone Baandrup
Lone Baandrup
RIRikke Ibsen
Rikke Ibsen
JKJakob Kjellberg
Jakob Kjellberg


31 March 2011 in The European Journal of Health Economics
Verified
Journal Article
Closed access
PDF file
LBLone Baandrup
Lone Baandrup
JSJan Sørensen
Jan Sørensen
HLHenrik Lublin
Henrik Lublin
MNMerete Nordentoft
Merete Nordentoft
BGBirte Glenthoj
Birte Glenthoj